Recent Updates
Recently added Catalysts
ZOAR Positive Sentiment

Zoar Limited Completes Business Combination with Impact Biomedical Inc.

Key Takeaway: Zoar Limited has successfully completed its business combination with Impact Biomedical Inc. and other entities. This strategic move aims to enhance Zoar's capabilities in developing complex active pharmaceutical ingredients. The company's ordinary shares are set to begin trading soon, reflecting a positive outlook for its future.

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful completion of business combination
  • Strengthens Zoar's position in the pharmaceutical market
  • Collaboration with Impact Biomedical Inc.

Full Press Release Details

HONG KONG--(BUSINESS WIRE)--Zoar Limited (NYSE American: ZOAR) (“Zoar” or the “Company”), a global pharmaceutical company focused on the development and manufacturing of complex active pharmaceutical ingredients (“APIs”) and intermediates, today announced that it has completed its business combination involving the Company, Impact Biomedical Inc. (“Impact”), Dr Ashleys Nevada Sub Inc. and Zoar Labs Limited (“Zoar Labs”) (the “Business Combination”). Zoar’s ordinary shares are expected to begin

Frequently Asked Questions

What companies are involved in the business combination?

The business combination involves Zoar Limited, Impact Biomedical Inc., and others.

What is the focus of Zoar Limited?

Zoar Limited focuses on developing complex active pharmaceutical ingredients.

When will Zoar's shares begin trading?

Zoar's ordinary shares are expected to begin trading soon after the merger.

What is the significance of this business combination?

This combination aims to strengthen Zoar's market position in pharmaceuticals.

Last updated: Nov 18, 2026